Transcriptional data from subsets of human tumors reveal that reduced expression of cGAS and STING correlates with poorer patient survival rates.182,213 High expression of STING is associated with lower pathological grading of glioma.214 Additionally, Tumor Treating Fields, a proven effective method for GBM treatment,215 has been found to mediate anti-tumor immunity and a cure rate of 42 to 66% through cGAS-STING and AIM-2 (Absent in Melanoma 2, a DNA sensor that activates the inflammasome) dependent pathways.216. The gene discussed is STING1; the disease is glioma.